{"doi":"10.1128/jcm.01844-18","title":"<i>In Vitro</i>\n            Susceptibility of Hepatitis C Virus Genotype 1 through 6 Clinical Isolates to the Pangenotypic NS3/4A Inhibitor Voxilaprevir","abstract":"<jats:p>Voxilaprevir is a direct-acting antiviral agent (DAA) that targets the NS3/4A protease of hepatitis C virus (HCV). High sequence diversity of HCV and inadequate drug exposure during unsuccessful treatment may lead to the accumulation of variants with reduced susceptibility to DAAs, including NS3/4A protease inhibitors such as voxilaprevir.</jats:p>","journal":"Journal of Clinical Microbiology","year":2019,"id":40121,"datarank":1.067108916021262,"base_score":2.70805020110221,"endowment":2.70805020110221,"self_citation_contribution":0.40620753016533157,"citation_network_contribution":0.6609013858559304,"self_endowment_contribution":0.40620753016533157,"citer_contribution":0.6609013858559304,"corpus_percentile":null,"corpus_rank":null,"citation_count":14,"citer_count":13,"citers_with_citation_signal":11,"citers_with_endowment":11,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":195478,"name":"Bandita Parhy","orcid":null,"position":1,"is_corresponding":false},{"id":195479,"name":"Julia Lu","orcid":null,"position":2,"is_corresponding":false},{"id":195480,"name":"Eric Zhou","orcid":null,"position":3,"is_corresponding":false},{"id":195481,"name":"David Hsieh","orcid":null,"position":4,"is_corresponding":false},{"id":195482,"name":"Gregory Camus","orcid":null,"position":5,"is_corresponding":false},{"id":195483,"name":"Ross Martin","orcid":null,"position":6,"is_corresponding":false},{"id":195484,"name":"Evguenia S. Svarovskaia","orcid":null,"position":7,"is_corresponding":false},{"id":195485,"name":"Hongmei Mo","orcid":null,"position":8,"is_corresponding":false},{"id":195486,"name":"Hadas Dvory-Sobol","orcid":null,"position":9,"is_corresponding":false},{"id":110860,"name":"Bin Han","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"base_score":2.70805020110221,"endowment":2.70805020110221,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"30728196","pmcid":"PMC6440772","openalex_id":"https://openalex.org/W2925231761","authors":[],"funders":[{"funder_name":"Gilead Sciences","grant_id":"","title":null}],"total_grants":1,"fwci":1.3442,"citation_percentile":0.79861827,"influential_citations":1,"citation_trend":[{"year":2019,"count":3},{"year":2020,"count":4},{"year":2021,"count":3},{"year":2023,"count":3},{"year":2025,"count":1}],"oa_status":"bronze","license":"https://journals.asm.org/non-commercial-tdm-license","oa_locations":[{"url":"https://jcm.asm.org/content/jcm/57/4/e01844-18.full.pdf","host_type":"journal"},{"url":"https://jcm.asm.org/content/jcm/57/4/e01844-18.full.pdf","host_type":"GREEN"},{"url":"https://jcm.asm.org/content/jcm/57/4/e01844-18.full.pdf","host_type":"publisher"},{"url":"https://journals.asm.org/doi/pdf/10.1128/JCM.01844-18","host_type":"publisher"},{"url":"https://doi.org/10.1128/jcm.01844-18","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/30728196","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/6440772","host_type":"repository"}],"fields_of_study":["Hepatitis C virus research","Hepatitis B Virus Studies","HIV/AIDS drug development and treatment","Biology","Medicine","Amino Acid Substitution","Aminoisobutyric Acids","Antiviral Agents","Cyclopropanes","Drug Resistance, Viral","Genotype","Hepacivirus","Hepatitis C, Chronic","Humans","Lactams, Macrocyclic","Leucine","Macrocyclic Compounds","Proline","Protease Inhibitors","Quinoxalines","Sulfonamides","Viral Nonstructural Proteins","Serine Endopeptidases","Nucleoside-Triphosphatase","DEAD-box RNA Helicases","Viral Proteases"],"mesh_terms":["Viral Proteases","Aminoisobutyric Acids","Antiviral Agents","Cyclopropanes","Genotype","Humans","Leucine","Proline","Protease Inhibitors","Quinoxalines","Serine Endopeptidases","Sulfonamides","Hepacivirus","Viral Nonstructural Proteins","Hepatitis C, Chronic","Amino Acid Substitution","Drug Resistance, Viral","Nucleoside-Triphosphatase","Macrocyclic Compounds","Lactams, Macrocyclic","DEAD-box RNA Helicases"],"keywords":["Virology","Genotype","NS3","Hepatitis C virus","In vitro","Biology","Flaviviridae","Hepacivirus","Virus","Microbiology","Medicine","Genetics","Gene","Resistance","Protease inhibitor","Clinical isolates","Direct-acting Antivirals","Pangenotypic","Resistance-associated Substitutions","Voxilaprevir"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[{"name":"gen"}],"source":"live","citation_network_status":"fetched"},"created_at":"2026-06-12T01:39:54.488996Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}